Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor pharmacokinetics after switching from Orkambi to Symkevi
NL-OMON47982Phase 4Active, not recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ivacaftor, lumacaftor and tezacaftor in cystic fibrosis (CF) (2 arms), sponsored by HagaZiekenhuis. Primary endpoint: Ivacaftor trough concentration. Started Aug 2019; status: active, not recruiting.
02
Drugs
ivacaftorlumacaftortezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON47982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47982.